• News
  • BioTech

Trovagene to begin collaboration with Dana-Farber Cancer Institute

San Diego-based Trovagene Inc. (Nasdaq: TROV) has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection, and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

Under the agreement, urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations.

A Dana-Farber oncology team, led by Dr. Jason Luke, will conduct clinical studies designed to monitor oncogene mutations in study subjects based on urinary cell-free DNA as an analytical specimen. Studies will be designed to collect data regarding the clinical status of patients, treatment effect, and long-term outcomes of therapy using Trovagene's non-invasive molecular diagnostic technology.

“While precision cancer treatments have made significant advances, current monitoring technologies are either invasive or do not provide specific genomic information to understand how the disease is responding to treatment at the molecular level,” said Dr. Luke. “Based on study data that Trovagene has presented at medical meetings thus far, we are encouraged that urinary cell-free DNA has potential to offer a non-invasive solution for tracking oncogene mutations during and after treatment, and this may help physicians improve patient outcomes.”

User Response
0 UserComments

Trovagene Inc.

Company Website

11055 Flintkote Ave.
San Diego, CA 92121

Trovagene Inc. Executive(s):

Antonius Schuh

  • Chief Executive Officer

Stephen Zaniboni

  • Chief Financial Officer